Global Ankylosing Spondylitis Market

Ankylosing Spondylitis Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral), Treatment Type (Nonsteroidal Anti-Inflammatory Drugs (Ibuprofen and Naproxen), Disease-Modifying Antirheumatic Drugs (Methotrexate), Biologics (Secukinumab, Certolizumab Pegol, and Infliximab)), Molecule Type (Small Molecules, Biologics, Biosimilars) Players and Region - Global Market Outlook to 2026

Ankylosing Spondylitis Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Ankylosing Spondylitis Market?

Ankylosing spondylitis (AS) is a type of arthritis that mostly affects the back. It causes infection in the joints of the spine, leading to pain and stiffness. Ankylosing spondylitis affects people in diverse ways some people can almost forget they have the condition, while for others it can have a big effect on their quality of life and sometimes joints other than those in the spine can be affected too. Sometimes, other parts of the body may also be affected. Ankylosing spondylitis is a type of spondyloarthritis is a group of conditions that share many of the same symptoms.

The market study is being classified, by Application (Hospitals, Clinics and Ambulatory Surgical Centers) and major geographies with country level break-up.

AbbVie Inc. (United States), Janssen Pharmaceuticals Inc. (Belgium), Pfizer Inc. (United States), Sandoz International GmbH (Germany), Amgen Inc. (United States), Protalix BioTherapeutics, Inc. (Israel), Reliance Life Sciences Pvt. Ltd. (India), Momenta Pharmaceuticals Inc. (United States), Celgene Corporation (United States), Regeneron Pharmaceuticals (United States) and Merck & Co. Inc. (United States) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Ankylosing Spondylitis market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Ankylosing Spondylitis market by Type, Application and Region.

On the basis of geography, the market of Ankylosing Spondylitis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Prevalence of Ankylosing Spondylitis
  • Rising Awareness about Diagnostics and Treatments

Market Trend
  • Increasing Number of Treatment Seeking Population

Restraints
  • High Cost of Treatment
  • Lack of Skilled Surgeons and Physiotherapists

Opportunities
  • Rising Research and Development Expenditure





Key Target Audience
Ankylosing Spondylitis Service Providers, Healthcare Industry, Regulatory Bodies and Governmental Bodies

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
By Route of Administration
  • Oral
  • Parenteral

By Treatment Type
  • Nonsteroidal Anti-Inflammatory Drugs [Ibuprofen and Naproxen]
  • Disease-Modifying Antirheumatic Drugs [Methotrexate]
  • Biologics [Secukinumab, Certolizumab Pegol, and Infliximab]

By Molecule Type
  • Small Molecules
  • Biologics
  • Biosimilars

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Ankylosing Spondylitis
      • 3.2.2. Rising Awareness about Diagnostics and Treatments
    • 3.3. Market Trends
      • 3.3.1. Increasing Number of Treatment Seeking Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ankylosing Spondylitis, by Application, Route of Administration, Treatment Type, Molecule Type and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Ankylosing Spondylitis (Value)
      • 5.2.1. Global Ankylosing Spondylitis by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Ambulatory Surgical Centers
      • 5.2.2. Global Ankylosing Spondylitis by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
      • 5.2.3. Global Ankylosing Spondylitis by: Treatment Type (Value)
        • 5.2.3.1. Nonsteroidal Anti-Inflammatory Drugs [Ibuprofen and Naproxen]
        • 5.2.3.2. Disease-Modifying Antirheumatic Drugs [Methotrexate]
        • 5.2.3.3. Biologics [Secukinumab, Certolizumab Pegol, and Infliximab]
      • 5.2.4. Global Ankylosing Spondylitis by: Molecule Type (Value)
        • 5.2.4.1. Small Molecules
        • 5.2.4.2. Biologics
        • 5.2.4.3. Biosimilars
      • 5.2.5. Global Ankylosing Spondylitis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Ankylosing Spondylitis (Price)
  • 6. Ankylosing Spondylitis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Janssen Pharmaceuticals Inc. (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sandoz International GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Protalix BioTherapeutics, Inc. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Reliance Life Sciences Pvt. Ltd. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Momenta Pharmaceuticals Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Celgene Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Regeneron Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Merck & Co. Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Ankylosing Spondylitis Sale, by Application, Route of Administration, Treatment Type, Molecule Type and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Ankylosing Spondylitis (Value)
      • 7.2.1. Global Ankylosing Spondylitis by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Ambulatory Surgical Centers
      • 7.2.2. Global Ankylosing Spondylitis by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
      • 7.2.3. Global Ankylosing Spondylitis by: Treatment Type (Value)
        • 7.2.3.1. Nonsteroidal Anti-Inflammatory Drugs [Ibuprofen and Naproxen]
        • 7.2.3.2. Disease-Modifying Antirheumatic Drugs [Methotrexate]
        • 7.2.3.3. Biologics [Secukinumab, Certolizumab Pegol, and Infliximab]
      • 7.2.4. Global Ankylosing Spondylitis by: Molecule Type (Value)
        • 7.2.4.1. Small Molecules
        • 7.2.4.2. Biologics
        • 7.2.4.3. Biosimilars
      • 7.2.5. Global Ankylosing Spondylitis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Ankylosing Spondylitis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ankylosing Spondylitis: by Application(USD Million)
  • Table 2. Ankylosing Spondylitis Hospitals , by Region USD Million (2015-2020)
  • Table 3. Ankylosing Spondylitis Clinics , by Region USD Million (2015-2020)
  • Table 4. Ankylosing Spondylitis Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 5. Ankylosing Spondylitis: by Route of Administration(USD Million)
  • Table 6. Ankylosing Spondylitis Oral , by Region USD Million (2015-2020)
  • Table 7. Ankylosing Spondylitis Parenteral , by Region USD Million (2015-2020)
  • Table 8. Ankylosing Spondylitis: by Treatment Type(USD Million)
  • Table 9. Ankylosing Spondylitis Nonsteroidal Anti-Inflammatory Drugs [Ibuprofen and Naproxen] , by Region USD Million (2015-2020)
  • Table 10. Ankylosing Spondylitis Disease-Modifying Antirheumatic Drugs [Methotrexate] , by Region USD Million (2015-2020)
  • Table 11. Ankylosing Spondylitis Biologics [Secukinumab, Certolizumab Pegol, and Infliximab] , by Region USD Million (2015-2020)
  • Table 12. Ankylosing Spondylitis: by Molecule Type(USD Million)
  • Table 13. Ankylosing Spondylitis Small Molecules , by Region USD Million (2015-2020)
  • Table 14. Ankylosing Spondylitis Biologics , by Region USD Million (2015-2020)
  • Table 15. Ankylosing Spondylitis Biosimilars , by Region USD Million (2015-2020)
  • Table 16. South America Ankylosing Spondylitis, by Country USD Million (2015-2020)
  • Table 17. South America Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 18. South America Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 19. South America Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 20. South America Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 21. Brazil Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 22. Brazil Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 23. Brazil Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 24. Brazil Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 25. Argentina Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 26. Argentina Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 27. Argentina Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 28. Argentina Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 29. Rest of South America Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 31. Rest of South America Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 32. Rest of South America Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 33. Asia Pacific Ankylosing Spondylitis, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 36. Asia Pacific Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 37. Asia Pacific Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 38. China Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 39. China Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 40. China Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 41. China Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 42. Japan Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 43. Japan Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 44. Japan Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 45. Japan Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 46. India Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 47. India Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 48. India Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 49. India Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 50. South Korea Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 51. South Korea Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 52. South Korea Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 53. South Korea Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 54. Taiwan Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 55. Taiwan Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 56. Taiwan Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 57. Taiwan Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 58. Australia Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 59. Australia Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 60. Australia Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 61. Australia Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 66. Europe Ankylosing Spondylitis, by Country USD Million (2015-2020)
  • Table 67. Europe Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 68. Europe Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 69. Europe Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 70. Europe Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 71. Germany Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 72. Germany Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 73. Germany Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 74. Germany Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 75. France Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 76. France Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 77. France Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 78. France Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 79. Italy Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 80. Italy Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 81. Italy Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 82. Italy Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 83. United Kingdom Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 84. United Kingdom Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 85. United Kingdom Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 86. United Kingdom Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 87. Netherlands Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 88. Netherlands Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 89. Netherlands Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 90. Netherlands Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 91. Rest of Europe Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 92. Rest of Europe Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 93. Rest of Europe Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 94. Rest of Europe Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 95. MEA Ankylosing Spondylitis, by Country USD Million (2015-2020)
  • Table 96. MEA Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 97. MEA Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 98. MEA Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 99. MEA Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 100. Middle East Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 101. Middle East Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 102. Middle East Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 103. Middle East Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 104. Africa Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 105. Africa Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 106. Africa Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 107. Africa Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 108. North America Ankylosing Spondylitis, by Country USD Million (2015-2020)
  • Table 109. North America Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 110. North America Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 111. North America Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 112. North America Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 113. United States Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 114. United States Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 115. United States Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 116. United States Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 117. Canada Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 118. Canada Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 119. Canada Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 120. Canada Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 121. Mexico Ankylosing Spondylitis, by Application USD Million (2015-2020)
  • Table 122. Mexico Ankylosing Spondylitis, by Route of Administration USD Million (2015-2020)
  • Table 123. Mexico Ankylosing Spondylitis, by Treatment Type USD Million (2015-2020)
  • Table 124. Mexico Ankylosing Spondylitis, by Molecule Type USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Ankylosing Spondylitis: by Application(USD Million)
  • Table 137. Ankylosing Spondylitis Hospitals , by Region USD Million (2021-2026)
  • Table 138. Ankylosing Spondylitis Clinics , by Region USD Million (2021-2026)
  • Table 139. Ankylosing Spondylitis Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 140. Ankylosing Spondylitis: by Route of Administration(USD Million)
  • Table 141. Ankylosing Spondylitis Oral , by Region USD Million (2021-2026)
  • Table 142. Ankylosing Spondylitis Parenteral , by Region USD Million (2021-2026)
  • Table 143. Ankylosing Spondylitis: by Treatment Type(USD Million)
  • Table 144. Ankylosing Spondylitis Nonsteroidal Anti-Inflammatory Drugs [Ibuprofen and Naproxen] , by Region USD Million (2021-2026)
  • Table 145. Ankylosing Spondylitis Disease-Modifying Antirheumatic Drugs [Methotrexate] , by Region USD Million (2021-2026)
  • Table 146. Ankylosing Spondylitis Biologics [Secukinumab, Certolizumab Pegol, and Infliximab] , by Region USD Million (2021-2026)
  • Table 147. Ankylosing Spondylitis: by Molecule Type(USD Million)
  • Table 148. Ankylosing Spondylitis Small Molecules , by Region USD Million (2021-2026)
  • Table 149. Ankylosing Spondylitis Biologics , by Region USD Million (2021-2026)
  • Table 150. Ankylosing Spondylitis Biosimilars , by Region USD Million (2021-2026)
  • Table 151. South America Ankylosing Spondylitis, by Country USD Million (2021-2026)
  • Table 152. South America Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 153. South America Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 154. South America Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 155. South America Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 156. Brazil Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 157. Brazil Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 158. Brazil Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 159. Brazil Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 160. Argentina Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 161. Argentina Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 162. Argentina Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 163. Argentina Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 164. Rest of South America Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 165. Rest of South America Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 166. Rest of South America Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 167. Rest of South America Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 168. Asia Pacific Ankylosing Spondylitis, by Country USD Million (2021-2026)
  • Table 169. Asia Pacific Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 170. Asia Pacific Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 171. Asia Pacific Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 172. Asia Pacific Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 173. China Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 174. China Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 175. China Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 176. China Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 177. Japan Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 178. Japan Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 179. Japan Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 180. Japan Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 181. India Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 182. India Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 183. India Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 184. India Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 185. South Korea Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 186. South Korea Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 187. South Korea Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 188. South Korea Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 189. Taiwan Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 190. Taiwan Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 191. Taiwan Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 192. Taiwan Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 193. Australia Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 194. Australia Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 195. Australia Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 196. Australia Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 197. Rest of Asia-Pacific Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 198. Rest of Asia-Pacific Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 201. Europe Ankylosing Spondylitis, by Country USD Million (2021-2026)
  • Table 202. Europe Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 203. Europe Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 204. Europe Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 205. Europe Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 206. Germany Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 207. Germany Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 208. Germany Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 209. Germany Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 210. France Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 211. France Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 212. France Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 213. France Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 214. Italy Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 215. Italy Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 216. Italy Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 217. Italy Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 218. United Kingdom Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 219. United Kingdom Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 220. United Kingdom Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 221. United Kingdom Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 222. Netherlands Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 223. Netherlands Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 224. Netherlands Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 225. Netherlands Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 226. Rest of Europe Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 227. Rest of Europe Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 228. Rest of Europe Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 229. Rest of Europe Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 230. MEA Ankylosing Spondylitis, by Country USD Million (2021-2026)
  • Table 231. MEA Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 232. MEA Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 233. MEA Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 234. MEA Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 235. Middle East Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 236. Middle East Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 237. Middle East Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 238. Middle East Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 239. Africa Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 240. Africa Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 241. Africa Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 242. Africa Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 243. North America Ankylosing Spondylitis, by Country USD Million (2021-2026)
  • Table 244. North America Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 245. North America Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 246. North America Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 247. North America Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 248. United States Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 249. United States Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 250. United States Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 251. United States Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 252. Canada Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 253. Canada Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 254. Canada Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 255. Canada Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 256. Mexico Ankylosing Spondylitis, by Application USD Million (2021-2026)
  • Table 257. Mexico Ankylosing Spondylitis, by Route of Administration USD Million (2021-2026)
  • Table 258. Mexico Ankylosing Spondylitis, by Treatment Type USD Million (2021-2026)
  • Table 259. Mexico Ankylosing Spondylitis, by Molecule Type USD Million (2021-2026)
  • Table 260. Research Programs/Design for This Report
  • Table 261. Key Data Information from Secondary Sources
  • Table 262. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ankylosing Spondylitis: by Application USD Million (2015-2020)
  • Figure 5. Global Ankylosing Spondylitis: by Route of Administration USD Million (2015-2020)
  • Figure 6. Global Ankylosing Spondylitis: by Treatment Type USD Million (2015-2020)
  • Figure 7. Global Ankylosing Spondylitis: by Molecule Type USD Million (2015-2020)
  • Figure 8. South America Ankylosing Spondylitis Share (%), by Country
  • Figure 9. Asia Pacific Ankylosing Spondylitis Share (%), by Country
  • Figure 10. Europe Ankylosing Spondylitis Share (%), by Country
  • Figure 11. MEA Ankylosing Spondylitis Share (%), by Country
  • Figure 12. North America Ankylosing Spondylitis Share (%), by Country
  • Figure 13. Global Ankylosing Spondylitis share by Players 2020 (%)
  • Figure 14. Global Ankylosing Spondylitis share by Players (Top 3) 2020(%)
  • Figure 15. Global Ankylosing Spondylitis share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Janssen Pharmaceuticals Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 20. Janssen Pharmaceuticals Inc. (Belgium) Revenue: by Geography 2020
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Sandoz International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Sandoz International GmbH (Germany) Revenue: by Geography 2020
  • Figure 25. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Protalix BioTherapeutics, Inc. (Israel) Revenue, Net Income and Gross profit
  • Figure 28. Protalix BioTherapeutics, Inc. (Israel) Revenue: by Geography 2020
  • Figure 29. Reliance Life Sciences Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 30. Reliance Life Sciences Pvt. Ltd. (India) Revenue: by Geography 2020
  • Figure 31. Momenta Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Momenta Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 34. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 35. Regeneron Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 36. Regeneron Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 37. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co. Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Global Ankylosing Spondylitis: by Application USD Million (2021-2026)
  • Figure 40. Global Ankylosing Spondylitis: by Route of Administration USD Million (2021-2026)
  • Figure 41. Global Ankylosing Spondylitis: by Treatment Type USD Million (2021-2026)
  • Figure 42. Global Ankylosing Spondylitis: by Molecule Type USD Million (2021-2026)
  • Figure 43. South America Ankylosing Spondylitis Share (%), by Country
  • Figure 44. Asia Pacific Ankylosing Spondylitis Share (%), by Country
  • Figure 45. Europe Ankylosing Spondylitis Share (%), by Country
  • Figure 46. MEA Ankylosing Spondylitis Share (%), by Country
  • Figure 47. North America Ankylosing Spondylitis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • Janssen Pharmaceuticals Inc. (Belgium)
  • Pfizer Inc. (United States)
  • Sandoz International GmbH (Germany)
  • Amgen Inc. (United States)
  • Protalix BioTherapeutics, Inc. (Israel)
  • Reliance Life Sciences Pvt. Ltd. (India)
  • Momenta Pharmaceuticals Inc. (United States)
  • Celgene Corporation (United States)
  • Regeneron Pharmaceuticals (United States)
  • Merck & Co. Inc. (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 220 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ankylosing Spondylitis Market Quantitative research analysis
Global Ankylosing Spondylitis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Prevalence of Ankylosing Spondylitis " is seen as one of major growth factors of Ankylosing Spondylitis Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Ankylosing Spondylitis Market in coming years.

Know More About Global Ankylosing Spondylitis Market Report?

Have a Query? Click Here

Other Related Reports

Infantile Spasms Therapeutics Comprehensive Study by Type (Monotherapy, Combination Therapy), Drug Form (Solid, Liquid), End Users (Infants, Children < 2 Years), Route of Administration (Oral, Parent...
$ 3500
Dry Eye Disease Comprehensive Study by Type (Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogue), Application (Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Ph...
$ 3450
Hypercalcemia Treatment Comprehensive Study by Application (Mild Hypercalcemia, Moderate Hypercalcemia, Severe Hypercalcemia), Treatment (Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidro...
$ 3650
Postpartum Hemorrhage Comprehensive Study by Type (Early Postpartum Hemorrhage, Late Postpartum Hemorrhage), Application (Hospitals, Clinics, Other), Drugs (Oxytocin, Prostaglandins (Dinoprostone, Mi...
$ 3750
Cancer Therapeutics and Biotherapeutics Comprehensive Study by Type (Chemotherapy, Radiation Therapy, Hormone Therapy, Biotherapy), Application (Household, Hospital, Others), Therapy Type (Monoclonal...
$ 3800
Anti-Aging Products and Therapies Comprehensive Study by Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid), Application (Anti-Pigmentation Therapy, Anti-Cellulite Tre...
$ 3750